White House Chronicle

News Analysis With a Sense of Humor

  • Home
  • King’s Commentaries
  • Random Features
  • Photos
  • Public Speaker
  • WHC Episodes
  • About WHC
  • Carrying Stations
  • ME/CFS Alert
  • Contact Us

How COVID-19 Points the Way to Faster Medicines in the Future

December 5, 2020 by Llewellyn King Leave a Comment

This is the month when the national spirit should start to lift: COVID-19 vaccines could be administered by mid-December. While we won’t reach the summit of a mighty mountain this month, nor well into next year, the ascent will have begun.

It is unlikely to be a smooth journey. There will be contention, accusation, litigation and frustration. Nothing so big as setting out to administer two-dose vaccines to the whole country could be otherwise.

But the pall which hangs so heavily over us with rising deaths, exhausted first responders and overstretched hospitals, will begin to lift very slightly.

For the rest of foreseeable history, there will be accusations leveled at the Trump administration for its handling of the pandemic — or its failure to handle it.

But one thing is certain: Our faith in our ability to make superhuman scientific efforts in the face of crisis will be restored. Developing a COVID-19 vaccine will be compared to putting a man on the moon.

The large pharmaceutical companies, known collectively as Big Pharma, have shown their muscle. The lesson: Throw enough research and unlimited money at a problem, accelerate the regulatory process and a solution can result.

Even globalization gets a good grade.

The first-to-market vaccine comes from American pharmaceutical giant Pfizer. But the vaccine was developed at its small German subsidiary, BioNTech, by a husband-and-wife team of first-generation Turkish immigrants. (Beware of whom you exclude.)

Biopharmaceutical research often takes place this way, akin to how it happens in Silicon Valley: Small companies innovate and invent, and larger ones gobble them up and provide the all-important resources for absurdly complicated and expensive clinical trials.

These contribute mightily to the cost of new drugs. A new “compound” -— as a drug is called in the trade — can cost up to $2 billion to bring to market; and financial reserves are needed, should there be costly lawsuits.

The development of new drugs looks like an inverted pyramid. Linda Marban, a researcher and CEO of Capricor Therapeutics, Inc., a clinical-stage biotechnology company based in Los Angeles, explained it to me:

“The last 20 years have shown a seismic change in how drugs and therapies are developed. Due to the speed at which science is advancing, and the difficulty of early-stage development, most of the early-stage work is done by small companies or the occasional academic. Big Pharma has moved into the role of late-stage clinical, sometimes Phase 2, but mostly Phase 3 and commercial development.”

In the upheaval occasioned by the pandemic, overhaul of the Food and Drug Administration (FDA) looms large as a national priority. It must be able — maybe with a greater use of artificial intelligence and data management — to assess the safety and efficiency of desperately needed drugs without the current painful and often fatal delays.

Marban said of the FDA clinical trials process:

“It is the most laborious and frustrating process which delays important scientific and medical discoveries from patients. There are many situations where patients are desperate for therapy, but we have to climb the long and ridiculous ladder of doing clinical trials due to inefficiencies at the site which include nearly endless layers of contracting, budget negotiations, IRB [Institutional Review Board] approvals and, finally, interest and attention from overworked clinical trial staff.”

This situation, according to Marban, is compounded by the FDA’s requirement for clinical trials conducted and presented in a certain way, which often precludes getting an effective therapy to market. “If we simplify this process alone, we could move rapidly towards treatments and even cures for many horrific diseases,” she added.

War is a time of upheaval, and we are at war against the COVID-19. But war also involves innovation. We have proved that speed is possible when bureaucracy is energized and streamlined.

When COVID-19 is finally vanquished, it should leave a legacy of better medical research and sped-up approval procedures, benefiting all going forward.

Email, RSS Follow
Email

Filed Under: King's Commentaries

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

White House Chronicle on Social

  • Facebook
  • Twitter
  • Vimeo
  • YouTube
Happy Birthday, America; Now Mind How You Go

Happy Birthday, America; Now Mind How You Go

Llewellyn King

Martin Walker, the gifted former Washington correspondent of The Guardian, used to start his speeches saying that the Fourth of July wasn’t a time for sorrow for him, as it was a time when good British yeomen farmers in the colonies revolted against a German king and his German mercenaries. Walker — who now lives […]

An Electric Revolution Is Underway, but Revolutions Are Messy

An Electric Revolution Is Underway, but Revolutions Are Messy

Llewellyn King

This, the 21st century, is set to be the electric century. We are in the middle of a profound electrification binge that is going to leave its mark, an electrical mark, on every aspect of human endeavor. I believed this before I attended the Edison Electric Institute annual meeting and convention in Orlando. Now I think […]

It Is the New Age of Creativity, Despite Shortages and Runaway Inflation

It Is the New Age of Creativity, Despite Shortages and Runaway Inflation

Llewellyn King

You could be excused for believing that everything is going to hell. We are living through a tumultuous time, and the next two years are going to be especially difficult with severe disruption to supply chains, runaway inflation and, worst of all, food shortages in much of the world. But it also may be a […]

Prepare for Blackouts Across the U.S. as Summer Takes Hold

Prepare for Blackouts Across the U.S. as Summer Takes Hold

Llewellyn King

Just when it didn’t seem things couldn’t get worse — gasoline at $5 to $8 a gallon, supply shortages in everything from baby formula to new cars — comes the devastating news that many of us will endure electricity blackouts this summer. The alarm was sounded by the nonprofit North American Electric Reliability Corp. and […]

Copyright © 2022 · White House Chronicle Theme on Genesis Framework · WordPress · Log in